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Hypertension (1) and atrial fibrillation (2,3) both increase 
with age. Both hypertension and atrial fibrillation are 
associated with an increased incidence of stroke, heart 
failure, and mortality (1-3). Hypertension and left 
ventricular hypertrophy caused by hypertension are major 
risk factors for atrial fibrillation (1). Hypertension is present 
in more than 80% of patients with atrial fibrillation (4). 
At  44-month fo l low-up of  2 ,384 o lder  pat ients , 
atrial fibrillation was a significant risk factor for new 
thromboembolic stroke with a risk ratio of 3.2, and left 
ventricular hypertrophy associated with hypertension was 
a significant independent risk factor for thromboembolic 
stroke with a risk ratio of 2.8 (5). At 36-month follow-up 
of 312 older patients with chronic atrial fibrillation, left 
ventricular hypertrophy associated with hypertension was 
a significant independent risk factor for thromboembolic 
stroke with a risk ratio of 2.8 (6). Hypertension is one of 
the risk factors for development of thromboembolic stroke 
in patients with atrial fibrillation in the CHADS2 (7) and 
CHA2DS2-VASc (8) scoring systems for risk of stroke. 
Hypertension is present in 74% of patients with congestive 
heart failure and in 77% of patients with a first stroke (9). 
Atrial fibrillation was present in 37% of 355 patients, mean 
age 80 years, with prior myocardial infarction, congestive 
heart failure, and a reduced left ventricular ejection fraction 
and in 33% of 296 patients, mean age 82 years, with prior 
myocardial infarction, congestive heart failure, and a 
preserved left ventricular ejection fraction (10). 
Hypertension is associated with left ventricular 
hypertrophy, impaired diastolic filling of the left ventricle, 
increased left atrial pressure, left atrial hypertrophy and 
enlargement, increased atrial fibrosis, increased atrial 
ectopic activity, and slowing of intra- and interatrial 
electrical conduction velocities (11). These changes 
in cardiac structure and physiology predispose to 
atrial fibrillation developing and increasing the risk of 
thromboembolic events (11). In patients who have atrial 
fibrillation, the presence of hypertension increases the 
incidence of stroke by an additional 2 to 3 times (12,13).
Adequate control of hypertension is indicated to reduce 
the risk of developing atrial fibrillation. A meta-analysis 
was performed in 11 randomized studies including 56,308 
patients which investigated whether treatment with 
angiotensin-converting enzyme inhibitors or angiotensin 
receptor blockers reduced the development of atrial 
fibrillation (14). The studies included four trials of patients 
with congestive heart failure, three trials of patients with 
hypertension, two trials after cardioversion for atrial 
fibrillation, and two trials after myocardial infarction. 
Overall, the use of angiotensin-converting enzyme 
inhibitors significantly reduced the risk of developing atrial 
fibrillation by 28%, and the use of angiotensin receptor 
blockers significantly reduced the risk of developing atrial 
fibrillation by 29%. The prevention of atrial fibrillation by 
angiotensin-converting enzyme inhibitors or angiotensin 
receptor blockers seemed limited to patients with heart 
failure who had a 44% significant reduction in the 
development of atrial fibrillation and to patients with 
hypertension and left ventricular hypertrophy who had 
a 29% significant reduction in the development of atrial 
fibrillation (14). The angiotensin-converting enzyme 
inhibitors probably reduce the risk of developing atrial 
fibrillation by reversing changes in cardiac structure and 
function (14). Angiotensin-converting enzyme inhibitors 
and angiotensin receptor blockers in animal models of heart 
failure have been demonstrated to reduce left atrial dilation, 
left atrial dysfunction, left atrial fibrosis, and shortening of 
the atrial refractory period, which should lead to a decrease 
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in the risk of atrial fibrillation (14,15). 
In the Losartan Intervention for Endpoint (LIFE) trial, 
8,851patients with hypertension and electrocardiographic 
left ventricular hypertrophy without atrial fibrillation were 
randomized to losartan or atenolol and followed for a 
mean duration of 4.8 years (16). Compared with atenolol, 
the incidence of atrial fibrillation that developed was 
significantly reduced by 33% despite similar blood pressure 
reduction by losartan and atenolol (16). The incidence 
of stroke in the patients who developed new-onset atrial 
fibrillation was also 51% lower in patients treated with 
losartan than in patients treated with atenolol (16). In the 
LIFE study, 342 patients with hypertension, left ventricular 
hypertrophy, and atrial fibrillation were randomized 
to losartan or to atenolol and followed up for 1,471 
patient years (17). The primary composite endpoint of 
cardiovascular mortality, stroke, and myocardial infarction 
was significantly reduced by 42% in the patients treated 
with losartan in these patients with hypertension, left 
ventricular hypertrophy, and atrial fibrillation (17).
Another meta-analysis was performed in 11 randomized 
controlled studies which included 55,971 patients which 
investigated whether treatment with angiotensin-converting 
enzyme inhibitors or angiotensin receptor blockers reduced 
the risk of development of atrial fibrillation (18). In three 
hypertension studies including 26,084 patients, compared 
with other antihypertensive drugs, treatment with an 
angiotensin-converting enzyme inhibitor or angiotensin 
receptor blocker significantly reduced the risk of developing 
atrial fibrillation by 23% (18). In three studies of 10,305 
patients with congestive heart failure, treatment with an 
angiotensin-converting enzyme inhibitor or angiotensin 
receptor blocker significantly reduced the risk of developing 
atrial fibrillation by 32% (18). In three studies of 317 
patients after electrical conversion of atrial fibrillation, 
treatment with an angiotensin-converting enzyme inhibitor 
or angiotensin receptor blocker significantly reduced the 
risk of developing atrial fibrillation by 51% (18). In two 
studies of 19,288 patients after myocardial infarction, 
treatment with an angiotensin-converting enzyme inhibitor 
or angiotensin receptor blocker significantly reduced the 
risk of developing atrial fibrillation by 10% (18). 
A third meta-analysis included ten randomized controlled 
trials in 42,892 patients with hypertension (19). In these 
trials, 20,491 patients were randomized to treatment with 
angiotensin-converting enzyme inhibitors or angiotensin 
receptor blockers and 22,401 patients to treatment with beta 
blockers or with calcium channel blockers. Treatment with 
ngiotensin-converting enzyme inhibitors or angiotensin 
receptor blockers significantly reduced the incidence of 
atrial fibrillation by 52% when compared to treatment with 
calcium channel blockers and by 61% when compared with 
beta blockers (19). Treatment with ngiotensin-converting 
enzyme inhibitors or angiotensin receptor blockers also 
significantly reduced the incidence of congestive heart failure 
by 14% when compared with treatment with calcium channel 
blockers or beta blockers but did not significantly reduce the 
incidence of new atrial fibrillation, cardiac death, myocardial 
infarction, and stroke when compared with treatment with 
calcium channel blockers or beta blockers (19).
Follow-up electrocardiograms were available for 
25,332 of 33,357 patients (76%) randomized to lisinopril, 
chlorthalidone, or amlodipine in the Antihypertensive and 
Lipid-Lowering Treatment to Prevent Heart Attack Trial 
(ALLHAT) (20). The incidence of new atrial fibrillation 
or atrial flutter did not differ significantly between patients 
treated with these three different antihypertensive drugs. 
However, the incidence of new atrial fibrillation or atrial 
flutter in 6,392 patients treated with doxazosin was 
significantly increased 1.3 times than in 11,695 patients 
treated with chlorthalidone (20).
In patients with hypertension, antihypertensive 
medications reduce the risk of stroke and of atrial 
fibrillation (1). Because patients with atrial fibrillation 
are at high risk for developing stroke, patients with atrial 
fibrillation and hypertension should especially have their 
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